|
1
|
Ghislain I, Zikos E, Coens C, Quinten C,
Balta V, Tryfonidis K, Piccart M, Zardavas D, Nagele E,
Bjelic-Radisic V, et al European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Group and Breast Cancer
Group; EORTC Headquarters, : Health-related quality of life in
locally advanced and metastatic breast cancer: Methodological and
clinical issues in randomised controlled trials. Lancet Oncol.
17:e294–e304. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Ma J, Goding Sauer A, Newman
LA and Jemal A: Breast cancer statistics, 2017, racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malvezzi M, Carioli G, Bertuccio P,
Boffetta P, Levi F, La Vecchia C and Negri E: European cancer
mortality predictions for the year 2019 with focus on breast
cancer. Ann Oncol. 30:781–787. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gao C, Li H, Zhuang J, Zhang H, Wang K,
Yang J, Liu C, Liu L, Zhou C and Sun C: The construction and
analysis of ceRNA networks in invasive breast cancer: A study based
on The Cancer Genome Atlas. Cancer Manag Res. 11:1–11. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meng X, Müller V, Milde-Langosch K,
Trillsch F, Pantel K and Schwarzenbach H: Diagnostic and prognostic
relevance of circulating exosomal miR-373, miR-200a, miR-200b and
miR-200c in patients with epithelial ovarian cancer. Oncotarget.
7:16923–16935. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu Y, Nangia-Makker P, Farhana L, G
Rajendra S, Levi E and Majumdar AP: miR-21 and miR-145 cooperation
in regulation of colon cancer stem cells. Mol Cancer. 14:982015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ying X, Wu Q, Wu X, Zhu Q and Wang X,
Jiang L, Chen X and Wang X: Epithelial ovarian cancer-secreted
exosomal miR-222-3p induces polarization of tumor-associated
macrophages. Oncotarget. 7:43076–43087. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mukohyama J, Shimono Y, Dalerba P, Isobe
T, Hu Q, Sahoo D, Shibuya N, Minami H, Mimori K, Kakeji Y, et al:
Epigenetic regulation of colorectal cancer stem cells by the
miR-221/QKI5 axis. Cancer Res. 78:4882018.
|
|
9
|
Fang Z, Zhong M, Wang Y, Yuan X, Guo H,
Yao Y, Feng M, Chen J, Xiong J and Xiang X: miR-381 and miR-489
suppress cell proliferation and invasion by targeting CUL4B via the
Wnt/β-catenin pathway in gastric cancer. Int J Oncol. 54:733–743.
2019.PubMed/NCBI
|
|
10
|
Xu D, Liu R, Meng L, Zhang Y, Lu G and Ma
P: Long non-coding RNA ENST01108 promotes carcinogenesis of glioma
by acting as a molecular sponge to modulate miR-489. Biomed
Pharmacother. 100:20–28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vergara-Ortega DN, Sevilla-Reyes EE,
Herrera-Ortiz A, Torres-Ibarra L, Salmerón J, Lazcano-Ponce E and
Sánchez- Alemán MA: Real time PCR to evaluate HSV-2 shedding from
anal and genital samples among men who have sex with men, living
with HIV. J Med Virol. 90:745–752. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh SK, Singh S, Lillard JW Jr and Singh
R: Drug delivery approaches for breast cancer. Int J Nanomedicine.
12:6205–6218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Welch HG, Prorok PC, O'Malley AJ and
Kramer BS: Breast-cancer tumor size, overdiagnosis, and mammography
screening effectiveness. N Engl J Med. 375:1438–1447. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burwinkel B, Cuk K, Zucknick M and
Madhavan D: Circulating miRNAs as markers for breast cancer. US
Patent 10,316,367. Filed June 21, 2013; issued June 11, 2019.
|
|
15
|
Sparano JA, Gray RJ, Makower DF, Pritchard
KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA
Jr, et al: Adjuvant chemotherapy guided by a 21-gene expression
assay in breast cancer. N Engl J Med. 379:111–121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cardoso F, van't Veer LJ, Bogaerts J,
Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S,
DeLorenzi M, et al MINDACT Investigators, : 70-gene signature as an
aid to treatment decisions in early-stage breast cancer. N Engl J
Med. 375:717–729. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Malih S, Saidijam M and Malih N: A brief
review on long noncoding RNAs: A new paradigm in breast cancer
pathogenesis, diagnosis and therapy. Tumour Biol. 37:1479–1485.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shah MY, Ferrajoli A, Sood AK,
Lopez-Berestein G and Calin GA: MicroRNA therapeutics in cancer -
an emerging concept. EBioMedicine. 12:34–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer - a brief overview. Adv Biol Regul. 57:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lou W, Liu J, Gao Y, Zhong G, Chen D, Shen
J, Bao C, Xu L, Pan J, Cheng J, et al: MicroRNAs in cancer
metastasis and angiogenesis. Oncotarget. 8:115787–115802. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Santolla MF, Lappano R, Cirillo F,
Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri
P, Di Martino MT, Maggiolini M, et al: miR-221 stimulates breast
cancer cells and cancer-associated fibroblasts (CAFs) through
selective interference with the A20/c-Rel/CTGF signaling. J Exp
Clin Cancer Res. 37:942018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao S, Liu H, Hou S, Wu L, Yang Z, Shen J,
Zhou L, Zheng SS and Jiang B: miR-489 suppresses tumor growth and
invasion by targeting HDAC7 in colorectal cancer. Clin Transl
Oncol. 20:703–712. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen X, Wang YW, Xing AY, Xiang S, Shi DB,
Liu L, Li YX and Gao P: Suppression of SPIN1-mediated PI3K-Akt
pathway by miR-489 increases chemosensitivity in breast cancer. J
Pathol. 239:459–472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roscigno G, Quintavalle C, Donnarumma E,
Puoti I, Diaz-Lagares A, Iaboni M, Fiore D, Russo V, Todaro M,
Romano G, et al: miR-221 promotes stemness of breast cancer cells
by targeting DNMT3b. Oncotarget. 7:580–592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Patel Y, Shah N, Lee JS, Markoutsa E, Jie
C, Liu S, Botbyl R, Reisman D, Xu P and Chen H: A novel
double-negative feedback loop between miR-489 and the
HER2-SHP2-MAPK signaling axis regulates breast cancer cell
proliferation and tumor growth. Oncotarget. 7:18295–18308. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan Y, Li J, Zhang Y, Wang N, Liang H, Liu
Y, Zhang CY, Zen K and Gu H: Slug-upregulated miR-221 promotes
breast cancer progression through suppressing E-cadherin
expression. Sci Rep. 6:257982016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ye Z, Hao R, Cai Y, Wang X and Huang G:
Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by
targeting the BIM-Bax/Bak axis in breast cancer. Tumour Biol.
37:4509–4515. 2016. View Article : Google Scholar : PubMed/NCBI
|
